Nuveen Asset Management LLC Sells 68,152 Shares of Quanterix Co. (NASDAQ:QTRX)

Nuveen Asset Management LLC lowered its stake in shares of Quanterix Co. (NASDAQ:QTRX - Free Report) by 11.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 539,093 shares of the company's stock after selling 68,152 shares during the period. Nuveen Asset Management LLC owned approximately 1.40% of Quanterix worth $5,731,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of the business. Bank of New York Mellon Corp lifted its holdings in shares of Quanterix by 1.8% during the 4th quarter. Bank of New York Mellon Corp now owns 108,186 shares of the company's stock valued at $1,150,000 after purchasing an additional 1,963 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Quanterix by 219.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,702 shares of the company's stock valued at $61,000 after purchasing an additional 3,915 shares in the last quarter. Hsbc Holdings PLC lifted its holdings in shares of Quanterix by 25.8% during the 4th quarter. Hsbc Holdings PLC now owns 19,371 shares of the company's stock valued at $205,000 after purchasing an additional 3,974 shares in the last quarter. Canada Pension Plan Investment Board lifted its holdings in shares of Quanterix by 64.5% during the 4th quarter. Canada Pension Plan Investment Board now owns 10,200 shares of the company's stock valued at $108,000 after purchasing an additional 4,000 shares in the last quarter. Finally, MetLife Investment Management LLC lifted its holdings in shares of Quanterix by 21.9% during the 4th quarter. MetLife Investment Management LLC now owns 23,983 shares of the company's stock valued at $255,000 after purchasing an additional 4,303 shares in the last quarter. Institutional investors own 86.48% of the company's stock.

Quanterix Price Performance

Shares of QTRX stock traded up $0.15 on Wednesday, hitting $5.58. 384,928 shares of the company's stock were exchanged, compared to its average volume of 577,617. Quanterix Co. has a 12 month low of $4.05 and a 12 month high of $19.18. The stock has a market cap of $216.67 million, a P/E ratio of -5.26 and a beta of 1.12. The company has a 50 day moving average of $5.36 and a 200 day moving average of $8.05.

Quanterix (NASDAQ:QTRX - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.16. The firm had revenue of $30.33 million during the quarter, compared to the consensus estimate of $28.27 million. Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. Sell-side analysts predict that Quanterix Co. will post -0.98 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on QTRX. Leerink Partners reiterated a "market perform" rating and set a $8.00 price objective (down previously from $12.00) on shares of Quanterix in a report on Wednesday, April 30th. Wall Street Zen cut Quanterix from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Leerink Partnrs cut Quanterix from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 30th. Canaccord Genuity Group dropped their target price on Quanterix from $15.00 to $12.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Finally, Scotiabank reissued an "outperform" rating on shares of Quanterix in a research report on Tuesday, March 25th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $15.60.

Quanterix Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.